Research programme: recombinant human acid ceramidase - Plexcera Therapeutics

Drug Profile

Research programme: recombinant human acid ceramidase - Plexcera Therapeutics

Alternative Names: Recombinant human acid ceramidase; rhAC; RVT-801

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer Enzyvant Sciences; Plexcera Therapeutics
  • Class Ceramidases
  • Mechanism of Action Acid ceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Farber lipogranulomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Farber lipogranulomatosis
  • Discontinued Cystic fibrosis

Most Recent Events

  • 02 Aug 2016 Discontinued - Preclinical for Cystic fibrosis in USA (Inhalation)
  • 12 Jul 2016 Preclinical development is ongoing in USA
  • 12 Jul 2016 Enzyvant Sciences announces intention to submit IND applications for clinical trials in Farber disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top